Business Context and Reporting Period
Company: Oric Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 12, 2024
Reporting Period: Fiscal quarter ended September 30, 2024
Context: This filing serves to announce the company's financial results for the third quarter of 2024 via a press release attached as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific numerical data. It references a press release (Exhibit 99.1) for details on:
- Revenue
- Profit/Loss
- Cash flow
- Margins
- Debt and liquidity positions
Note: The filing text does not provide clear values for these metrics.
Material Changes
The filing text does not disclose specific material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for comparative analysis.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates by reference a press release containing management's discussion of results, but the text of the commentary is not included in this document.
Legal Disclaimer: The information furnished in Item 2.02 and Item 9.01 (including the press release) is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 12, 2024) for actual financial figures.
- Verify the specific revenue and net loss figures for the quarter ended September 30, 2024.
- Check the press release for updated cash runway and liquidity status.
- Confirm any changes in clinical trial progress or regulatory milestones mentioned in the full press release.